Nervosave Therapeutics discovers and develops therapies that slow, stop and reverse a broad range of demyelinating peripheral nerve diseases.
Our first aim is to develop best in class Gene Therapy for CMT1A patients and beyond for all demyelinating CMT diseases.
We develop robust discovery programs targeting both CMT diseases and acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Cap Omega, Rond Point Benjamin Franklin, Montpellier,please Select 34000,france
- Industry
- Biotechnology
- Website
- http://nervosavetx.com
- Keywords
- des patients.
- HQ
- Montpellier, Please Select
Nervosave Therapeutics Questions
Nervosave Therapeutics's website is http://nervosavetx.com
Nervosave Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/nervosave-therapeutics
Nervosave Therapeutics has
4 employees.
View email and phone details for 4
employees at Nervosave Therapeutics.
Nervosave Therapeutics's industry is
Biotechnology
Nervosave Therapeutics's top competitors are
Regenlife,
Novagray,
Cilcare,
Nbx Bio,
Greenphage,
Surgimab Sas,
Ai-Stroke,
Aporepair,
Stent Up,
Phost'in Therapeutics.
Nervosave Therapeutics's categories are Biotechnology
Nervosave Therapeutics's founding year is 2021
